HIV Evolution, Epidemiology and Prevention
Full Professor, Microbiology and Molecular Biology, Instituto Superior de Ciências da Saúde Egas Moniz
Group Leader, HIV Evolution, Epidemiology and Prevention at iMed.ULisboa
We sequence the full-length or partial genomes of HIV, Yellow Fever virus, HCV, and other viruses and use phylogenetic analysis and resistance mutation analysis to characterize the epidemiology, transmission dynamics, diversity and molecular evolution of these viruses in Portugal, Angola, Mozambique and Cape Verde. The epidemiologic data contributes for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), Institute of Health Metrics and Evaluation, Washington, USA. The sequence data along with virus isolates and their genomic material is used in the production/validation of new diagnostic tests, implementation of better treatment regimens, and development of new antiviral drugs as well as new vaccine and microbicide candidates. We also perform the pre-clinical evaluation of novel vaccine and microbicide candidates and new drugs for the treatment, prevention and cure of HIV infection.
Phenotypic, genetic, evolutionary and structural analysis of virus isolates from patients residing in Portuguese speaking countries provides basic information enabling the characterization of epidemic trends in each of the countries, the definition of better diagnostic, treatment and prevention strategies and the development of new drugs and vaccines
Source: Aga Khan Development Network (AKDN) – Portugal Collaborative Research Network in Portuguese speaking countries in Africa.
Title: Epidemiology, drug resistance and pathogenesis of HIV in Cape Verde: the Cape Verde HIV Cohort.
PI: Nuno Taveira
Source: RIA2016MC-1615, European & Developing Countries Clinical Trials Partnership (EDCTP), UE.
Title: Neonatal HIV early infant diagnosis (EID) versus standard of care EID – Impact on inFant hEalth: a feasibility study of point-of care testing at birth versus at 6 weeks of age, on the uptake of ART and infant prophylaxis, and on rates of infant survival, morbidity and retention in care.
PI: Ilesh Jani; Participant: Nuno Taveira, as responsible for Work Package 5 (Basic Virology studies).
Source: NIH, USA (R-00260-15-0)
Title: Reconstructing HIV epidemics from HIV phylogenetics.
PI: Thomas Leitner, Los Alamos National Lab, USA; Participant: Nuno Taveira
Recent Most Relevant Publications
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390:1211-1259.
Rocha C1, Duarte J, Borrego P, Calado R, Marcelino JM, Tendeiro R, Valadas E, Sousa AE, Taveira N. Potency of HIV-2-specific antibodies increase in direct association with loss of memory B cells. AIDS 2017; 31: 2431-2433.
Romero-Severson EO, Bulla I, Hengartner N, Bártolo I, Abecasis A, Azevedo-Pereira JM, Taveira N, Leitner T. Donor-recipient identification in para- and poly-phyletic trees under alternative HIV-1 transmission hypotheses using approximate Bayesian computation. Genetics 2017; 207: 1089-1101.
Borrego P, Gonçalves MF, Gomes P, Araújo L, Moranguinho I, Figueiredo IB, Barahona I, Rocha J, Mendonça C, Cruz MC, Barreto J, Taveira N. Assessment of the Cavidi ExaVir™ Load assay for monitoring plasma viral load in HIV-2 infected patients. J Clin Microbiol 2017; 55: 2367-2379.
Kraemer MUG, Faria NR, Reiner RC, Golding N, Nikolay B, Johansson MA, Salje H, Faye O, Wint GRW, Niedrig M, Shearer FM, Hill SC, Thompson RN, Bisanzio D, Taveira N, Nax H, Pradelski BSR, Murphy NR, Bogoch II, Khan K, Brownstein JS, Tatem AJ, de Oliveira T, Smith DL, Sall A, Pybus OG, Hay SI, Cauchemez S. Spread of Yellow Fever Virus outbreak in Angola and the Democratic Republic Congo 2015-2016: a modelling study. Lancet Infect Dis 2017; 17: 330-338.